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Dear Editor,
We thank F. Skobieranda, S. Candler, and W. Macfadden from
Jazz Pharmaceuticals, Inc. for their comment on “Once-Nightly
Sodium Oxybate (FT218) Demonstrated Improvement of
Symptoms in a Phase 3 Randomized Clinical Trial in Patients
With Narcolepsy.” We appreciate their recognition of how this
research will expand the legacy of sodium oxybate, which is the
established gold standard in the treatment of narcolepsy.
Skobieranda et al. comment on the study design and discussion of efficacy and safety of FT218, or ON-SXB, as well as other
oxybate formulations. REST-ON was conducted under a Special
Protocol Agreement (SPA) assessment with the Food and Drug
Administration (FDA), which is reached when the FDA agrees
with the “adequacy and acceptability of specific critical elements of overall protocol design (e.g., entry criteria, dose selection, endpoints, and planned analyses)” allowing the study to
be considered adequate and well-controlled to support a New
Drug Application [1]. The ON-SXB trial design used a placebocontrolled evaluation of three therapeutic doses (6, 7.5, and 9 g)

of ON-SXB, with evaluation at three prespecified endpoints:
week 3 for 6 g, week 8 for 7.5 g, and week 13 for 9 g [2], similar to
the dose escalation used in clinical practice.
The second comment is about the discussion of efficacy and
tolerability rates. As noted in the publication, the discussion
section explicitly stated that cross-trial comparisons should
be interpreted with caution owing to different trial designs [2].
Given that clinicians and their patients may have a choice of 3
oxybate therapies if ON-SXB is FDA approved, the recognition of
efficacy and safety data generated through these separate trials
is relevant. Skobieranda et al. attribute the lack of efficacy observed with the 6-g dose of immediate-release, twice-nightly
sodium oxybate (Xyrem) [3], in part to the shorter duration (4
weeks compared to 13 weeks). As described in the REST-ON trial
design, the evaluation of ON-SXB 6 g occurred at week 3 [2].
The third comment focused on the relative tolerability
of once-nightly vs twice-nightly oxybate. The rates cited for
ON-SXB were also treatment-emergent adverse events, not adverse reactions. Furthermore, the cited treatment-emergent
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consultant for Jazz Pharmaceuticals, Takeda Pharmaceutical Co.,
Orexo, Avadel Pharmaceuticals, Eisai, Merck & Co., and Idorsia.
C.M.S. is a consultant and has served on speakers bureaus for
Avadel Pharmaceuticals and Jazz Pharmaceuticals. A.R. has
received grant/research support from Jazz Pharmaceuticals,
Suven, Inspire, Nyxoah, LivaNova, and Avadel Pharmaceuticals;
is a consultant for Jazz Pharmaceuticals, Suven, Inspire, and
Avadel Pharmaceuticals; and has served on speakers bureaus
for Jazz Pharmaceuticals and Eisai. R.R. received research grant
funding from Avadel Pharmaceuticals to conduct the current
study. He has also received research grant support from Jazz
Pharmaceuticals, Eisai, Merck & Co., Apnimed, Inc., Idorsia,
Biohaven, and Suven Life Sciences Ltd. He has participated in
advisory boards for Jazz Pharmaceuticals, Eisai, and Harmony
Biosciences. A.O.A. is a consultant for Avadel Pharmaceuticals
and is a consultant and has served on speakers bureau for Jazz
Pharmaceuticals.

Disclaimer
At the time of publication, there is an ongoing litigation between
Jazz Pharmaceuticals and Avadel Pharmaceuticals.

Data Availability
All relevant data are included within the text.
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adverse events were obtained from the published Jazz literature, in which events with a p value of <.05 were considered
related [3].
The letter authors contest the notion that falls related to the
middle-of-the-night dosing may potentially be lessened with
a single bedtime dose and remind readers that the Xyrem and
Xywav Prescribing Information advise patients to stay in bed
after the second dose [4, 5], guidance that was added to the labeling in 2014 based on postmarketing surveillance reports. Falls
may occur with any oxybate formulation. If ON-SXB is FDA approved, clinical practice will likely elucidate whether a single
bedtime dose mitigates this risk.
The final comment focuses on the lower sodium included in
the recently introduced mixed-salt oxybates. Sodium oxybate,
which contains approximately 1600 mg of sodium at its highest
dose, has been used in the United States for nearly 20 years and
in Europe for more than 15 years, providing a robust dataset
to analyze for potential correlation to cardiovascular disease.
When a comprehensive review of the literature was undertaken,
no association between sodium oxybate use and cardiovascular
disease was identified [6]. Beyond these reassuring findings, debate exists over the appropriate recommended threshold for sodium intake; the European Society of Cardiology has asserted
that a population-level mean target below 5,000 mg per day is
reasonable [7].
Sodium oxybate remains underutilized 2 decades later after
its introduction in 2002. We realize that innovation in medicine is often incrementally achieved, evolving the status quo.
It is our sincere hope that if ON-SXB is approved by the FDA,
the 3 oxybate formulations will allow clinicians to have a more
patient-centered, personalized medicine approach to narcolepsy care by enabling them to prescribe the oxybate medication
that best meets their patients’ individual needs.

